Navigation Links
Scott & White Healthcare researcher finds success with new anti-cancer drug
Date:12/22/2009

A study conducted at Scott & White Healthcare in Temple, Texas, found that a new drug stopped the growth of breast tumors in mice. This drug is unique in that it works both by stopping the cancer cells from growing and metastasizing to other organs, and by stimulating the immune system to destroy breast cancer cells and keeps them from coming back. This is the only drug that's able to work in both ways, while all other treatments work in one way or another. And, this research initiative not only involves physicians and biologists working together to bring treatments from the laboratory to the bedside, but a unique third component agriculturalists.

Researcher Alexzander Asea, Ph.D., the Effie and Wofford Cain Endowed Chair in Clinical Pathology, and division chief of investigative pathology at Scott & White Healthcare and the Texas A&M Health Science Center, said "we found that some of the mice were essentially cured."

"All anti-cancer drugs broadly fall into two categories; either directly killing cancer cells (often healthy cells as well), or vaccines that help sick patients by boosting the immune system to better fight off cancer. This new drug works both ways, as a vaccine by taking away the cancer cell ability to grow, multiply and spread to distant organs, and by educating the immune system to recognize the breast cancer cells as 'foreign invaders' that need to be attacked and destroyed and to continue that process over time," Dr. Asea said.

Dr. Asea went on to say "breast cancer cells fly under the radar of the immune system, by turning off the machinery that normally puts recognition structures on the surface of cancer cells which the immune system uses to recognize and destroy them. To overcome this problem, this injectable drug turns on this machinery within the cancer cells allowing the immune system to recognize the cancer cells and kill them. The unique thing is that the revved-up immune cells will continue patrolling for any hidden cancer cells months and years after the last cancer cells have been killed," Dr. Asea said.

"Collaborating with the agricultural community on this research also allows us to use a special delivery mechanism of the drug that doesn't cause the negative side effects you see with more traditional treatments like chemotherapeutic agents," explained Dr. Asea.

Dr. Asea said only about one year of additional work is required before Phase I clinical trials can begin in women with metastatic breast cancer at Scott & White Hospital. "However, this stage requires a significant amount of funding. We're currently looking at various sources including federal, state and private sources to get this promising drug to the patients who need it."


'/>"/>

Contact: Katherine Voss
kvoss@swmail.sw.org
254-724-4097
Scott & White Healthcare
Source:Eurekalert

Related biology news :

1. American Society for Microbiology honors D. Scott Merrell
2. TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
3. Phoenix conference highlights TGens and Scottsdale Healthcares contributions to molecular oncology
4. TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug
5. Wolf reintroduction proposed in Scottish Highland test case
6. Scott & White Healthcare researcher finds success with new anti-cancer drug
7. ESA honored at White House ceremony
8. Unveiling the underwater ways of the white shark
9. New whitepaper offers options for university implementation of NIH policy
10. Clumps of red and white blood cells may contribute to sickle cell disease
11. White House science office needs upgrade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... DIEGO , June 27, 2016  Sequenom, Inc. ... committed to enabling healthier lives through the development of ... Court of the United States ... courts that the claims of Sequenom,s U.S. Patent No. ... patent eligibility criteria established by the Supreme Court,s Mayo ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former ... of the University of North Carolina Kenan-Flagler Business School effective June ... UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes and ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
Breaking Biology Technology: